Atıf İçin Kopyala
ALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., Turgut M., AKSU S., SAYINALP N., ...Daha Fazla
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, sa.8, ss.1851-1856, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
50
Sayı:
8
-
Basım Tarihi:
2020
-
Doi Numarası:
10.3906/sag-2001-173
-
Dergi Adı:
TURKISH JOURNAL OF MEDICAL SCIENCES
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.1851-1856
-
Anahtar Kelimeler:
Multiple myeloma, CD34(+) hematopoietic progenitor cell, engraftment, survival, BLOOD, MOBILIZATION, GUIDELINES, MANAGEMENT, COLLECTION, DIAGNOSIS, LYMPHOMA
-
Ondokuz Mayıs Üniversitesi Adresli:
Evet
Özet
Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34(+) hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 x 10(6)/kg. The aim of this study was to evaluate the relationship between the dose of CD3V4(+). HPCs and survival in MM patients who underwent AHSCT at a tertiary care center.